STOCK TITAN

Surrozen Stock Price, News & Analysis

SRZN NASDAQ

Company Description

Overview

Surrozen Inc (SRZN) is a clinical-stage biotechnology company devoted to the discovery and development of innovative regenerative medicines that harness the power of the body’s natural repair mechanisms. Utilizing advanced tissue-specific antibody platforms, the company focuses on modulating the Wnt signaling pathway, a critical mediator in tissue repair and regeneration, to create novel therapeutics for severe liver and ocular diseases. With a solid foundation in cutting-edge research, Surrozen has built its expertise from the work of its founding scientists, who bring extensive experience from prestigious academic institutions.

Core Therapeutic Focus

The company’s core approach is centered on Wnt pathway modulation for tissue regeneration. Surrozen is actively developing drug candidates designed to selectively enhance Wnt signaling, facilitating effective tissue repair in conditions that traditionally have limited treatment options. By strategically targeting the pathway, the company addresses regenerative needs in organs such as the liver and retina, thereby opening avenues for novel therapeutic interventions in diseases like severe alcohol-associated hepatitis, retinal vascular disorders, and ocular degenerative conditions.

Innovative Technology Platforms

Surrozen leverages proprietary antibody platforms including SWEETS and SWAP, which are engineered to mimic and enhance the natural activities of Wnt proteins. These approaches enable the creation of bispecific antibodies that can precisely activate the Wnt pathway in targeted tissues. This specificity is critical for minimizing off-target effects while maximizing regenerative outcomes, and it underscores the company’s commitment to developing therapies that are both innovative and safe.

Operational and Clinical Excellence

Currently in the clinical phase, Surrozen’s robust pipeline includes multiple drug candidates undergoing or advancing through early phase clinical trials. These studies are designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamic responses, with early data demonstrating acceptable safety profiles and evidence of target engagement. The clinical programs underscore a methodical approach to drug development, reflecting deep expertise in designing trials that address unmet medical needs.

Strategic Market Position

In a competitive biotechnology landscape, Surrozen distinguishes itself through its scientific rigor and specialized focus on regenerative mechanisms. The company’s reliance on advanced antibody engineering and precise modulation of the Wnt pathway positions it uniquely in the drug development arena. By focusing on clear clinical endpoints and leveraging partnerships with established industry leaders, Surrozen reinforces its credibility and authority as it seeks to provide transformative solutions in the treatment of severe liver and retinal diseases.

Industry and Scientific Relevance

Surrozen’s activities resonate deeply within the biotechnology sector, where the understanding and manipulation of critical signaling pathways remain central to therapeutic innovation. The company’s approach is backed by extensive research and development, making it a valuable source of expertise regarding the subset of therapeutics that employ regenerative and tissue-specific antibody modalities. Its scientific publications and strategic collaborations further underscore the company’s contribution to advancing the field of regenerative medicine.

Conclusion

Overall, Surrozen Inc exemplifies the modern clinical-stage biotechnology firm: dedicated to unlocking complex biological processes through state-of-the-art antibody engineering and focused on addressing significant unmet clinical needs. Its in-depth knowledge of the Wnt pathway and commitment to regenerative medicine underscore a strategy built on scientific innovation and methodological rigor, making Surrozen a vital point of reference for investors and stakeholders seeking comprehensive insights into cutting-edge therapeutic development.

Stock Performance

$11.53
-0.26%
0.03
Last updated: September 27, 2025 at 15:58
-22.6 %
Performance 1 year
$102.2M

SEC Filings

No SEC filings available for Surrozen.

Financial Highlights

$10,000,000
Revenue (TTM)
-$1,434,000
Net Income (TTM)
-$6,752,000
Operating Cash Flow

Upcoming Events

JAN
01
January 1, 2026 - December 31, 2026 Regulatory

IND submission for SZN-8141

Submission of IND application for SZN-8141 to FDA during 2026
JAN
01
January 1, 2026 Regulatory

Expected IND FDA clearance

JAN
01
January 1, 2026 Regulatory

IND filing for SZN-8141/SZN-8143

Short Interest History

Last 12 Months
Loading short interest data...

Days to Cover History

Last 12 Months
Loading days to cover data...

Frequently Asked Questions

What is the current stock price of Surrozen (SRZN)?

The current stock price of Surrozen (SRZN) is $11.56 as of September 26, 2025.

What is the market cap of Surrozen (SRZN)?

The market cap of Surrozen (SRZN) is approximately 102.2M. Learn more about what market capitalization means .

What is the revenue (TTM) of Surrozen (SRZN) stock?

The trailing twelve months (TTM) revenue of Surrozen (SRZN) is $10,000,000.

What is the net income of Surrozen (SRZN)?

The trailing twelve months (TTM) net income of Surrozen (SRZN) is -$1,434,000.

What is the earnings per share (EPS) of Surrozen (SRZN)?

The diluted earnings per share (EPS) of Surrozen (SRZN) is -$0.44 on a trailing twelve months (TTM) basis. Learn more about EPS .

What is the operating cash flow of Surrozen (SRZN)?

The operating cash flow of Surrozen (SRZN) is -$6,752,000. Learn about cash flow.

What is the profit margin of Surrozen (SRZN)?

The net profit margin of Surrozen (SRZN) is -14.34%. Learn about profit margins.

What is the operating margin of Surrozen (SRZN)?

The operating profit margin of Surrozen (SRZN) is 12.32%. Learn about operating margins.

What is the current ratio of Surrozen (SRZN)?

The current ratio of Surrozen (SRZN) is 7.40, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.

What is the operating income of Surrozen (SRZN)?

The operating income of Surrozen (SRZN) is $1,232,000. Learn about operating income.

What is the core focus of Surrozen Inc?

Surrozen is dedicated to discovering and developing regenerative medicines by selectively modulating the Wnt pathway to promote tissue repair, particularly in the liver and eye.

How does Surrozen’s technology work?

The company uses proprietary platforms such as SWEETS and SWAP to engineer tissue-specific bispecific antibodies that activate key Wnt signaling components, thereby enhancing natural regenerative processes.

What therapeutic areas is Surrozen targeting?

Surrozen primarily focuses on severe liver diseases, such as alcohol-associated hepatitis, and ocular conditions related to retinal and corneal degenerations.

How far along are Surrozen’s clinical trials?

Surrozen is in the clinical stage with several drug candidates undergoing early phase trials that assess safety, target engagement, and pharmacodynamic effects in patients and healthy volunteers.

What is the significance of modulating the Wnt pathway?

The Wnt pathway plays a crucial role in tissue development and repair. By modulating this pathway, Surrozen strives to activate the body’s innate repair mechanisms, offering innovative therapeutic options for degenerative diseases.

Who are the founders of Surrozen and what expertise do they bring?

Surrozen was founded by leading scientists with academic backgrounds from elite institutions, including experts in molecular biology and regenerative medicine, who contribute deep research insights into Wnt signaling.

How does Surrozen differentiate itself in the competitive biotech landscape?

Surrozen distinguishes itself through its focused approach on regenerative therapies via targeted Wnt pathway modulation, its innovative antibody engineering platforms, and strategic clinical trial designs that emphasize safety and tissue-specific effects.

What benefits do investors gain from understanding Surrozen’s business model?

Understanding Surrozen’s robust R&D approach, clinical strategy, and its innovative technology platforms provides insights into how the company is addressing significant unmet medical needs, establishing a solid foundation of expertise and authority in regenerative medicine.